Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome

NCT05413356 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Bronchiolitis Obliterans Syndrome
Hematologic Malignancy

Interventions

DRUG: Ruxolitinib

Sponsor

First Affiliated Hospital of Zhejiang University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]